Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies solutions to early-stage drug development from lead candidate selection to clinical proof of concept, has completed the acquisition of Sinclair Research, a preclinical CRO located in the Midwest. Complementing existing locations on the East and West Coast, the new site will facilitate even greater access to Altasciences’ preclinical services across the U.S.
 
“This acquisition will add significant capacity and expertise to Altasciences’ existing preclinical offering,” said Steve Mason, co-chief operating officer, Altasciences. “Sinclair’s experience conducting research on a wide variety of species in a comprehensive range of drug classes will broaden our current preclinical offering and support Altasciences’ focus on providing our clients with customized solutions.”
 
With over 80 animal rooms, Sinclair Research is a large nonclinical CRO in the U.S., providing full-service IND and NDA-enabling toxicology and safety pharmacology services. Built on more than 50 years of experience, Sinclair Research provides services to support biopharmaceutical, animal health, and medical device development programs. “We are very excited to be joining the Altasciences team, and look forward to being able to offer our preclinical services to a broader market by leveraging the resources and expertise of an integrated, global CRO,” said Guy Bouchard, CEO, Sinclair Research.
 
Chris Perkin, CEO, Altasciences, said, “With this acquisition, Altasciences is continuing to advance its strategic growth plan to provide an expanded range of services in support of our integrated early-phase drug development solutions. Sinclair Research shares our commitment to animal welfare, and we look forward to merging our talents and working together with our new team of preclinical experts in the Midwest.”